Univ Paris Est Créteil, INSERM U955, IMRB, Translational Neuro-Psychiatry, F-94010 Créteil, France; AP-HP, Hôpitaux Universitaires Henri Mondor, Département Médico-Universitaire de Psychiatrie et d'Addictologie (DMU IMPACT), Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT) F-94010, France; La Fondation FondaMental, F-94010 Créteil, France; Child Mind Institute, New York, USA.
La Fondation FondaMental, F-94010 Créteil, France; AP-HP Health Economics Research Unit, Hotel Dieu Hospital, INSERM UMR 1153 CRESS, Paris, France.
Eur Neuropsychopharmacol. 2023 Apr;69:87-95. doi: 10.1016/j.euroneuro.2023.02.004. Epub 2023 Mar 21.
Mental disorders often begin early in life and constitute five of the top ten causes of disability. Their total cost across Europe is estimated at more than 4% of GDP (more than € 600 billion). The last study investigating the cost of mental disorders in France by our group was based on data from 2007 and yielded an estimated indirect and direct cost of € 109 billions. The objective of this study was thus to provide an overall updated cost of mental health in France ten years later and before the COVID-19 pandemic. We estimated the costs related to the direct healthcare and medico-social system, loss of productivity and loss of quality of life. We conducted a literature search to identify direct healthcare, medico-social, indirect (loss of productivity and income compensation) and loss of quality of life during 2018. We included costs related to major psychiatric disorders, including autism and intellectual disability, but excluded the costs related to dementia. Our estimate of the total cost of mental disorders in France, including medical (14%), social (8%), indirect (27%) and loss of quality of life (51%), was € 163 billions in 2018. This total cost includes money spend, forgone earnings and DALYs lost. We found a 50% increase in costs relative to our previous 2007 study. Large-scale cost-effective interventions such as specialized consultations or the development of ambulatory care could help decrease direct healthcare costs related to hospitalization and productivity loss while greatly improving the quality of life of patients.
精神障碍通常在生命早期开始，并构成十大残疾原因中的五种。在整个欧洲，其总成本估计超过 GDP 的 4%（超过 6000 亿欧元）。我们小组最近一次调查法国精神障碍成本的研究是基于 2007 年的数据，估计间接和直接成本为 1090 亿欧元。因此，本研究的目的是在 COVID-19 大流行之前，提供法国精神健康成本的最新十年综合更新。我们估计了与直接医疗保健和医疗社会系统、生产力损失和生活质量损失相关的成本。我们进行了文献检索，以确定 2018 年直接医疗保健、医疗社会、间接（生产力损失和收入补偿）和生活质量损失方面的成本。我们包括了与主要精神障碍相关的成本，包括自闭症和智力残疾，但排除了与痴呆症相关的成本。我们估计法国精神障碍的总成本包括医疗（14%）、社会（8%）、间接（27%）和生活质量损失（51%），为 2018 年的 1630 亿欧元。这总成本包括花费的资金、放弃的收益和失去的 DALYs。我们发现与我们之前的 2007 年研究相比，成本增加了 50%。大规模的具有成本效益的干预措施，如专门的咨询或门诊服务的发展，可以帮助减少与住院和生产力损失相关的直接医疗保健成本，同时极大地提高患者的生活质量。
